|Day Low/High||61.68 / 62.23|
|52 Wk Low/High||54.24 / 68.12|
Icahn may have a tough time finding interest in this behemoth.
Here's why the pharmaceutical company is a solid addition to your portfolio.
The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
An update of earnings, payout dates and upcoming dividend reminders.
Would get drugs to market faster and possibly more cheaply.
- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
The biotech saw shares fall 2.3% after reporting in-line earnings and worse-than-expected revenue.
Value stocks will extend their outperformance over growth stocks that began last year.
What do you do when the music stops? Are you the kid without a chair?
On Friday, investors will get quarterly results from American Airlines and the release of fourth quarter gross domestic product.
- Initiation of Phase 2 clinical trial programs in early Alzheimer's disease and progressive supranuclear palsy (PSP) is part of ongoing commitment to investigate ABBV-8E12 and tau-focused approaches to delay disease progression
- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis
The weak companies could be clobbered.
- This marks the seventh FDA approval and fifth disease indication for IMBRUVICA since the medication's initial approval in 2013
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
Earnings previews, company updates, dividend reminders -- the works.
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
The stock has gained 15% over the past year and we maintain the company is attractive to purchase for the secure payout.